Pharmacogenetics of the nuclear hormone receptors: The missing link between environment and drug effects?

Pharmacogenomics

Volumn 14, Issue 16, 2013, Pages 2035-2054

  De Mattia, Elena ^a   Dreussi, Eva ^a   Cecchin, Erika ^a   Toffoli, Giuseppe ^a  

^a CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

Author keywords

cancer; drug metabolizing enzymes; environment; nuclear receptors; pharmacogenetics; polymorphisms; PXR; therapy; transporters

Indexed keywords

BORTEZOMIB; CARBOPLATIN; CISPLATIN; CONSTITUTIVE ANDROSTANE RECEPTOR; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; DEXAMETHASONE; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; FARNESOID X RECEPTOR; FIRTECAN; HEPATOCYTE NUCLEAR FACTOR 4ALPHA; HORMONE RECEPTOR; HYDROCORTISONE; MERCAPTOPURINE; METHOTREXATE; PACLITAXEL; PAZOPANIB; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PREGNANE X RECEPTOR; RETINOID X RECEPTOR; SUNITINIB; TAMOXIFEN; THALIDOMIDE; VINCRISTINE; VITAMIN D RECEPTOR;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADVANCED CANCER; BONE NECROSIS; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER RESISTANCE; CAR GENE; CASTRATION RESISTANT PROSTATE CANCER; DRUG EFFICACY; DRUG RESPONSE; ESOPHAGITIS; FEBRILE NEUTROPENIA; HNF4A GENE; HUMAN; KIDNEY CANCER; KIDNEY CARCINOMA; LEUKOPENIA; LUNG NON SMALL CELL CANCER; METABOLIC DISORDER; METASTASIS; MULTIPLE MYELOMA; NEUROLOGIC DISEASE; NEUROPATHY; NEUTROPENIA; PERIPHERAL NEUROPATHY; PHARMACOGENETICS; PHENOTYPE; PNEUMONIA; PROTEIN EXPRESSION; PXR GENE; REVIEW; SIDE EFFECT; SINGLE NUCLEOTIDE POLYMORPHISM; VDR GENE; VITAMIN SUPPLEMENTATION; WEIGHT GAIN;

ANTINEOPLASTIC AGENTS; ATP-BINDING CASSETTE TRANSPORTERS; GENE EXPRESSION REGULATION; GENE-ENVIRONMENT INTERACTION; HUMANS; METABOLIC DETOXICATION, PHASE I; METABOLIC DETOXICATION, PHASE II; PHARMACOGENETICS; RECEPTORS, CYTOPLASMIC AND NUCLEAR; XENOBIOTICS;

EID: 84889015245     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.13.214     Document Type: Review

References (98)

1. Cecchin E, Innocenti F, D'Andrea M et al. Predictive role of the UGT1A1, UGT1A7, and UGT1A9 genetic variants and their haplotypes on the outcome of metastatic colorectal cancer patients treated with fluorouracil, leucovorin, and irinotecan. J. Clin. Oncol. 27(15), 2457-2465 (2009).
2. De Mattia E, Toffoli G, Polesel J et al. Pharmacogenetics of ABC and SLC transporters in metastatic colorectal cancer patients receiving first-line FOLFIRI treatment. Pharmacogenet. Genomics 23(10), 549-557 (2013).
3. Dreussi E, Biason P, Toffoli G, Cecchin E. miRNA pharmacogenomics: the new frontier for personalized medicine in cancer? Pharmacogenomics 13(14), 1635-1650 (2012).
4. Evrard A, Mbatchi L. Genetic polymorphisms of drug metabolizing enzymes and transporters: the long way from bench to bedside. Curr. Top. Med. Chem. 12(15), 1720-1729 (2012).
5. Cressman AM, Petrovic V, Piquette-Miller M. Inflammation-mediated changes in drug transporter expression/activity: implications for therapeutic drug response. Expert Rev. Clin. Pharmacol. 5(1), 69-89 (2012).
6. Zanger UM, Schwab M. Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol. Ther. 138(1), 103-141 (2013).
7. Chen Y, Tang Y, Guo C, Wang J, Boral D, Nie D. Nuclear receptors in the multidrug resistance through the regulation of drug-metabolizing enzymes and drug transporters. Biochem. Pharmacol. 83(8), 1112-1126 (2012).
8. Xu C, Li CY, Kong AN. Induction of phase I, II and III drug metabolism/transport by xenobiotics. Arch. Pharm. Res. 28(3), 249-268 (2005).
9. Chai X, Zeng S, Xie W. Nuclear receptors PXR and CAR: implications for drug metabolism regulation, pharmacogenomics and beyond. Expert Opin. Drug Metab. Toxicol. 9(3), 253-266 (2013).
10. Mukherjee S, Mani S. Orphan nuclear receptors as targets for drug development. Pharm. Res. 27(8), 1439-1468 (2010).
11. Krasowski MD, Ni A, Hagey LR, Ekins S. Evolution of promiscuous nuclear hormone receptors: LXR, FXR, VDR, PXR, and CAR. Mol. Cell. Endocrinol. 334(1-2), 39-48 (2011).
12. Plum LA, DeLuca HF. Vitamin D, disease and therapeutic opportunities. Nat. Rev. Drug Discov. 9(12), 941-955 (2010).
13. Pondugula SR, Mani S. Pregnane xenobiotic receptor in cancer pathogenesis and therapeutic response. Cancer Lett. 328(1), 1-9 (2013).
14. Harmsen S, Meijerman I, Beijnen JH, Schellens JH. The role of nuclear receptors in pharmacokinetic drug-drug interactions in oncology. Cancer Treat. Rev. 33(4), 369-380 (2007).
15. Dawson MI, Xia Z. The retinoid X receptors and their ligands. Biochim. Biophys. Acta 1821(1), 21-56 (2012).
16. Koutsounas I, Patsouris E, Theocharis S. Pregnane X receptor and human malignancy. Histol. Histopathol. 28(4), 405-420 (2013).
17. Raynal C, Pascussi JM, Leguelinel G et al. Pregnane X receptor (PXR) expression in colorectal cancer cells restricts irinotecan chemosensitivity through enhanced SN-38 glucuronidation. Mol. Cancer 9, 46 (2010).
18. Harmsen S, Meijerman I, Febus CL, Maas-Bakker RF, Beijnen JH, Schellens JH. PXR-mediated induction of P-glycoprotein by anticancer drugs in a human colon adenocarcinoma-derived cell line. Cancer Chemother. Pharmacol. 66(4), 765-771 (2010).
19. Zhou J, Liu M, Zhai Y, Xie W. The antiapoptotic role of pregnane X receptor in human colon cancer cells. Mol. Endocrinol. 22(4), 868-880 (2008).
20. Jiang H, Chen K, He J et al. Association of pregnane X receptor with multidrug resistance-related protein 3 and its role in human colon cancer chemoresistance. J. Gastrointest. Surg. 13(10), 1831-1838 (2009).
21. Chen Y, Tang Y, Chen S, Nie D. Regulation of drug resistance by human pregnane X receptor in breast cancer. Cancer Biol. Ther. 8(13), 1265-1272 (2009).
22. Choi HK, Yang JW, Roh SH, Han CY, Kang KW. Induction of multidrug resistance associated protein 2 in tamoxifen-resistant breast cancer cells. Endocr. Relat. Cancer 14(2), 293-303 (2007).
23. Conde I, Lobo MV, Zamora J et al. Human pregnane X receptor is expressed in breast carcinomas, potential heterodimers formation between hPXR and RXR-alpha. BMC Cancer 8, 174 (2008).
24. Gupta D, Venkatesh M, Wang H et al. Expanding the roles for pregnane X receptor in cancer: proliferation and drug resistance in ovarian cancer. Clin. Cancer Res. 14(17), 5332-5340 (2008).
25. Masuyama H, Nakatsukasa H, Takamoto N, Hiramatsu Y. Down-regulation of pregnane X receptor contributes to cell growth inhibition and apoptosis by anticancer agents in endometrial cancer cells. Mol. Pharmacol. 72(4), 1045-1053 (2007).
26. Chen Y, Tang Y, Wang MT, Zeng S, Nie D. Human pregnane X receptor and resistance to chemotherapy in prostate cancer. Cancer Res. 67(21), 10361-10367 (2007).
27. Kumar S, Jaiswal B, Kumar S, Negi S, Tyagi RK. Cross-talk between androgen receptor and pregnane and xenobiotic receptor reveals existence of a novel modulatory action of anti-androgenic drugs. Biochem. Pharmacol. 80(7), 964-976 (2010).
28. Wang T, Ma X, Krausz KW, Idle JR, Gonzalez FJ. Role of pregnane X receptor in control of all-trans retinoic acid (ATRA) metabolism and its potential contribution to ATRA resistance. J. Pharmacol. Exp. Ther. 324(2), 674-684 (2008).
29. Mensah-Osman EJ, Thomas DG, Tabb MM et al. Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer 109(5), 957-965 (2007).
30. Taghizadeh F, Tang MJ, Tai IT. Synergism between vitamin D and secreted protein acidic and rich in cysteine-induced apoptosis and growth inhibition results in increased susceptibility of therapy-resistant colorectal cancer cells to chemotherapy. Mol. Cancer Ther. 6(1), 309-317 (2007).
31. Kota BP, Allen JD, Roufogalis BD. The effect of vitamin D3 and ketoconazole combination on VDR-mediated P-gp expression and function in human colon adenocarcinoma cells: implications in drug disposition and resistance. Basic Clin. Pharmacol. Toxicol. 109(2), 97-102 (2011).
32. Larriba MJ, Munoz A. SNAIL vs vitamin D receptor expression in colon cancer: therapeutics implications. Br. J. Cancer 92(6), 985-989 (2005).
33. Alagbala AA, Moser MT, Johnson CS, Trump DL, Foster BA. Characterization of vitamin D insensitive prostate cancer cells. J. Steroid Biochem. Mol. Biol. 103(3-5), 712-716 (2007).
34. Swami S, Krishnan AV, Feldman D. Vitamin D metabolism and action in the prostate: implications for health and disease. Mol. Cell. Endocrinol. 347(1-2), 61-69 (2011).
35. Zhan L, Zhang H, Zhang Q et al. Regulatory role of KEAP1 and NRF2 in PPAR gamma expression and chemoresistance in human non-small-cell lung carcinoma cells. Free Radic. Biol. Med. 53(4), 758-768 (2012).
36. Han EJ, Im CN, Park SH, Moon EY, Hong SH. Combined treatment with peroxisome proliferator-activated receptor (PPAR) gamma ligands and gamma radiation induces apoptosis by PPARgamma-independent up-regulation of reactive oxygen species-induced deoxyribonucleic acid damage signals in non-small cell lung cancer cells. Int. J. Radiat. Oncol. Biol. Phys. 85(5), e239-e248 (2013).
37. Mansure JJ, Nassim R, Chevalier S et al. A novel mechanism of PPAR gamma induction via EGFR signalling constitutes rational for combination therapy in bladder cancer. PLoS ONE 8(2), e55997 (2013).
38. Wang L, Giannoudis A, Austin G, Clark RE. Peroxisome proliferator- activated receptor activation increases imatinib uptake and killing of chronic myeloid leukemia cells. Exp. Hematol. 40(10), 811-819 (2012).
39. Chen YZ, Xue JY, Chen CM et al. PPAR signaling pathway may be an important predictor of breast cancer response to neoadjuvant chemotherapy. Cancer Chemother. Pharmacol. 70(5), 637-644 (2012).
40. Swales KE, Korbonits M, Carpenter R, Walsh DT, Warner TD, Bishop-Bailey D. The farnesoid X receptor is expressed in breast cancer and regulates apoptosis and aromatase expression. Cancer Res. 66(20), 10120-10126 (2006).
41. Herraez E, Gonzalez-Sanchez E, Vaquero J et al. Cisplatin-induced chemoresistance in colon cancer cells involves FXR-dependent and FXR-independent up-regulation of ABC proteins. Mol. Pharm. 9(9), 2565-2576 (2012).
42. Chellappa K, Robertson GR, Sladek FM. HNF4 alpha: a new biomarker in colon cancer? Biomark. Med. 6(3), 297-300 (2012).
43. Hoskins JM, Carey LA, McLeod HL. CYP2D6 and tamoxifen: DNA matters in breast cancer. Nat. Rev. Cancer 9(8), 576-586 (2009).
44. Poon AH, Gong L, Brasch-Andersen C et al. Very important pharmacogene summary for VDR. Pharmacogenet. Genomics 22(10), 758-763 (2012).
45. Zhang B, Xie W, Krasowski MD. PXR: a xenobiotic receptor of diverse function implicated in pharmacogenetics. Pharmacogenomics 9(11), 1695-1709 (2008).
46. Kiyotani K, Mushiroda T, Kubo M, Zembutsu H, Sugiyama Y, Nakamura Y. Association of genetic polymorphisms in SLCO1B3 and ABCC2 with docetaxel-induced leukopenia. Cancer Sci. 99(5), 967-972 (2008).
47. Baker SD, Li J, Ten Tije AJ et al. Relationship of systemic exposure to unbound docetaxel and neutropenia. Clin. Pharmacol. Ther. 77(1), 43-53 (2005).
48. Tham LS, Holford NH, Hor SY et al. Lack of association of single-nucleotide polymorphisms in pregnane X receptor, hepatic nuclear factor 4 alpha, and constitutive androstane receptor with docetaxel pharmacokinetics. Clin. Cancer Res. 13(23), 7126-7132 (2007).
49. Hor SY, Lee SC, Wong CI et al. PXR, CAR and HNF 4alpha genotypes and their association with pharmacokinetics and pharmacodynamics of docetaxel and doxorubicin in Asian patients. Pharmacogenomics J. 8(2), 139-146 (2008).
50. Tang NL, Liao CD, Wang X et al. Role of pharmacogenetics on adjuvant chemotherapy-induced neutropenia in Chinese breast cancer patients. J. Cancer Res. Clin. Oncol. 139(3), 419-427 (2013).
51. Sandanaraj E, Lal S, Selvarajan V et al. PXR pharmacogenetics: association of haplotypes with hepatic CYP3A4 and ABCB1 messenger RNA expression and doxorubicin clearance in Asian breast cancer patients. Clin. Cancer Res. 14(21), 7116-7126 (2008).
52. van Erp NP, Eechoute K, van der Veldt AA et al. Pharmacogenetic pathway analysis for determination of sunitinib-induced toxicity. J. Clin. Oncol. 27(26), 4406-4412 (2009).
53. Kim H, Kang HJ, Kim HJ et al. Pharmacogenetic analysis of pediatric patients with acute lymphoblastic leukemia: a possible association between survival rate and ITPA polymorphism. PLoS ONE 7(9), e45558 (2012).
54. Broyl A, Corthals SL, Jongen JL et al. Mechanisms of peripheral neuropathy associated with bortezomib and vincristine in patients with newly diagnosed multiple myeloma: a prospective analysis of data from the HOVON-65/GMMG-HD4 trial. Lancet Oncol. 11(11), 1057-1065 (2010).
55. Johnson DC, Corthals SL, Walker BA et al. Genetic factors underlying the risk of thalidomide-related neuropathy in patients with multiple myeloma. J. Clin. Oncol. 29(7), 797-804 (2011).
56. Deeken JF, Cormier T, Price DK et al. A pharmacogenetic study of docetaxel and thalidomide in patients with castration-resistant prostate cancer using the DMET genotyping platform. Pharmacogenomics J. 10(3), 191-199 (2010).
57. Eisman JA. Pharmacogenetics of the vitamin D receptor and osteoporosis. Drug Metab. Dispos. 29(4 Pt 2), 505-512 (2001).
58. Nakamura M, Morimoto S, Ogihara T, Kakudo K. The worldwide controversy about the polymorphism of the vitamin D receptor gene and bone mineral density. Med. Hypotheses 54(3), 495-497 (2000).
59. Relling MV, Yang W, Das S et al. Pharmacogenetic risk factors for osteonecrosis of the hip among children with leukemia. J. Clin. Oncol. 22(19), 3930-3936 (2004).
60. French D, Hamilton LH, Mattano LA et al. A PAI-1 (SERPINE1) polymorphism predicts osteonecrosis in children with acute lymphoblastic leukemia: a report from the children's oncology group. Blood 111(9), 4496-4499 (2008).
61. te Winkel ML, van Beek RD, de Muinck Keizer-Schrama SM et al. Pharmacogenetic risk factors for altered bone mineral density and body composition in pediatric acute lymphoblastic leukemia. Haematologica 95(5), 752-759 (2010).
62. Beuselinck B, Karadimou A, Lambrechts D et al. Single-nucleotide polymorphisms associated with outcome in metastatic renal cell carcinoma treated with sunitinib. Br. J. Cancer 108(4), 887-900 (2013).
63. van der Veldt AA, Eechoute K, Gelderblom H et al. Genetic polymorphisms associated with a prolonged progression-free survival in patients with metastatic renal cell cancer treated with sunitinib. Clin. Cancer Res. 17(3), 620-629 (2011).
64. Xu C, Ball HA, Bing N et al. Association of genetic markers in angiogenesis-or exposure-related genes with overall survival in pazopanib (P) treated patients (pts) with advanced renal cell carcinoma. J. Clin. Oncol. 29(Suppl. 7), Abstract 303 (2011).
65. Xu CF, Bing NX, Ball HA et al. Pazopanib efficacy in renal cell carcinoma: evidence for predictive genetic markers in angiogenesis-related and exposure-related genes. J. Clin. Oncol. 29(18), 2557-2564 (2011).
66. Gandara DR, Kawaguchi T, Crowley J et al. Japanese-US common-arm analysis of paclitaxel plus carboplatin in advanced non-small-cell lung cancer: a model for assessing population-related pharmacogenomics. J. Clin. Oncol. 27(21), 3540-3546 (2009).
67. Lundin AC, Soderkvist P, Eriksson B, Bergman-Jungestrom M, Wingren S. Association of breast cancer progression with a vitamin D receptor gene polymorphism. South-East Sweden Breast Cancer Group. Cancer Res. 59(10), 2332-2334 (1999).
68. Rocha JC, Cheng C, Liu W et al. Pharmacogenetics of outcome in children with acute lymphoblastic leukemia. Blood 105(12), 4752-4758 (2005).
69. Davies SM, Borowitz MJ, Rosner GL et al. Pharmacogenetics of minimal residual disease response in children with B-precursor acute lymphoblastic leukemia: a report from the children's oncology group. Blood 111(6), 2984-2990 (2008).
70. Pao JB, Yang YP, Huang CN et al. Vitamin D receptor gene variants and clinical outcomes after androgen-deprivation therapy for prostate cancer. World J. Urol. 31(2), 281-287 (2013).
71. Xiong L, Cheng J, Gao J, Wang J, Liu X, Wang L. Vitamin D receptor genetic variants are associated with chemotherapy response and prognosis in patients with advanced non-small-cell lung cancer. Clin. Lung Cancer 14(4), 433-439 (2013).
72. Cortes CP, Siccardi M, Chaikan A, Owen A, Zhang G, La Porte CJ. Correlates of efavirenz exposure in Chilean patients affected with human immunodeficiency virus reveals a novel association with a polymorphism in the constitutive androstane receptor. Ther. Drug Monit. 35(1), 78-83 (2013).
73. Wyen C, Hendra H, Siccardi M et al. Cytochrome P450 2B6 (CYP2B6 ) and constitutive androstane receptor (CAR) polymorphisms are associated with early discontinuation of efavirenz-containing regimens. J. Antimicrob. Chemother. 66(9), 2092-2098 (2011).
74. Dobrinas M, Cornuz J, Eap CB. Pharmacogenetics of CYP1A2 activity and inducibility in smokers and exsmokers. Pharmacogenet. Genomics 23(5), 286-292 (2013).
75. Zhang J, Kuehl P, Green ED et al. The human pregnane X receptor: genomic structure and identification and functional characterization of natural allelic variants. Pharmacogenetics 11(7), 555-572 (2001).
76. Andrews E, Armstrong M, Tugwood J et al. A role for the pregnane X receptor in flucloxacillin-induced liver injury. Hepatology 51(5), 1656-1664 (2010).
77. Glas J, Seiderer J, Fischer D et al. Pregnane X receptor (PXR/NR1I2) gene haplotypes modulate susceptibility to inflammatory bowel disease. Inflamm. Bowel Dis. 17(9), 1917-1924 (2011).
78. Arai H, Miyamoto K, Taketani Y et al. A vitamin D receptor gene polymorphism in the translation initiation codon: effect on protein activity and relation to bone mineral density in Japanese women. J. Bone Miner. Res. 12(6), 915-921 (1997).
79. Jurutka PW, Remus LS, Whitfield GK et al. The polymorphic N terminus in human vitamin D receptor isoforms influences transcriptional activity by modulating interaction with transcription factor IIB. Mol. Endocrinol. 14(3), 401-420 (2000).
80. Thirumaran RK, Lamba JK, Kim RB et al. Intestinal CYP3A4 and midazolam disposition in vivo associate with VDR polymorphisms and show seasonal variation. Biochem. Pharmacol. 84(1), 104-112 (2012).
81. Uitterlinden AG, Fang Y, van Meurs JB, Pols HA, van Leeuwen JP. Genetics and biology of vitamin D receptor polymorphisms. Gene 338(2), 143-156 (2004).
82. Luo XY, Yang MH, Wu FX et al. Vitamin D receptor gene BsmI polymorphism B allele, but not BB genotype, is associated with systemic lupus erythematosus in a Han Chinese population. Lupus 21(1), 53-59 (2012).
83. Lee JJ, Wu X, Hildebrandt MA et al. Global assessment of genetic variation influencing response to retinoid chemoprevention in head and neck cancer patients. Cancer Prev. Res. (Phila.) 4(2), 185-193 (2011).
84. Schulman IG. Nuclear receptors as drug targets for metabolic disease. Adv. Drug Deliv. Rev. 62(13), 1307-1315 (2010).
85. Fiorucci S, Distrutti E, Bifulco G, D'Auria MV, Zampella A. Marine sponge steroids as nuclear receptor ligands. Trends Pharmacol. Sci. 33(11), 591-601 (2012).
86. Festa C, De Marino S, Sepe V et al. Solomonamides A and B, new anti-inflammatory peptides from Theonella swinhoei. Org. Lett. 13(6), 1532-1535 (2011).
87. Hermann TW, Yen WC, Tooker P et al. The retinoid X receptor agonist bexarotene (Targretin) synergistically enhances the growth inhibitory activity of cytotoxic drugs in non-small cell lung cancer cells. Lung Cancer 50(1), 9-18 (2005).
88. Yen WC, Prudente RY, Lamph WW. Synergistic effect of a retinoid X receptor-selective ligand bexarotene (LGD1069, Targretin) and paclitaxel (Taxol) in mammary carcinoma. Breast Cancer Res. Treat. 88(2), 141-148 (2004).
89. Blumenschein GR, Khuri FR, von Pawel J et al. Phase III trial comparing carboplatin, paclitaxel, and bexarotene with carboplatin and paclitaxel in chemotherapy-naive patients with advanced or metastatic non-small-cell lung cancer: SPIRIT II. J. Clin. Oncol. 26(11), 1879-1885 (2008).
90. Ramlau R, Zatloukal P, Jassem J et al. Randomized Phase III trial comparing bexarotene (L1069-49)/cisplatin/vinorelbine with cisplatin/vinorelbine in chemotherapy-naive patients with advanced or metastatic non-small-cell lung cancer: SPIRIT I. J. Clin. Oncol. 26(11), 1886-1892 (2008).
91. Takagi S, Nakajima M, Mohri T, Yokoi T. Post-transcriptional regulation of human pregnane X receptor by micro-RNA affects the expression of cytochrome P450 3A4. J. Biol. Chem. 283(15), 9674-9680 (2008).
92. Wirsing A, Senkel S, Klein-Hitpass L, Ryffel GU. A systematic analysis of the 3́UTR of HNF4A mRNA reveals an interplay of regulatory elements including miRNA target sites. PLoS ONE 6(11), e27438 (2011).
93. Ramamoorthy A, Li L, Gaedigk A et al. In silico and in vitro identification of microRNAs that regulate hepatic nuclear factor 4alpha expression. Drug Metab. Dispos. 40(4), 726-733 (2012).
94. Hildebrandt MA, Komaki R, Liao Z et al. Genetic variants in inflammation-related genes are associated with radiation-induced toxicity following treatment for non-small cell lung cancer. PLoS ONE 5(8), e12402 (2010).
95. Yamaguchi H, Hishinuma T, Endo N et al. Genetic variation in ABCB1 influences paclitaxel pharmacokinetics in Japanese patients with ovarian cancer. Int. J. Gynecol. Cancer 16(3), 979-985 (2006).
96. Lim HS, Ju LH, Seok LK, Sook LE, Jang IJ, Ro J. Clinical implications of CYP2D6 genotypes predictive of tamoxifen pharmacokinetics in metastatic breast cancer. J. Clin. Oncol. 25(25), 3837-3845 (2007).
97. Kishi S, Yang W, Boureau B et al. Effects of prednisone and genetic polymorphisms on etoposide disposition in children with acute lymphoblastic leukemia. Blood 103(1), 67-72 (2004).
98. Pande M, Thompson PA, Do KA et al. Genetic variants in the vitamin D pathway and breast cancer disease-free survival. Carcinogenesis 34(3), 587-594 (2013).